Extended Data Fig. 6: LIMIT cis-activates GBPs to boost MHC-I and tumor immunity.
From: LIMIT is an immunogenic lncRNA in cancer immunity and immunotherapy
a-b, Fold changes of Limit expression upon IFNγ treatment in YUMM1.7 cells (a) or CT26 cells (b) stably carrying shFluc, shLimit a, or shLimit b. mean ± SD, n = 3 biological independent samples, P value by 2-sided t-test. c, A375 cells were transfected with LIMIT cDNA for 24 hours. RNA levels of indicated genes were determined by qRT-PCR. mean ± SD, n = 3 biological independent samples, P value by 2-sided t-test. d, RPKM of Gbp family members upon IFNγ treatment in B16 cells (GSE99299). mean ± SD, n = 3 biological independent samples. e, A375 shFluc or shLIMIT cells were overexpressed with GBP1 (GBP1OE), and treated with IFNγ for 48 hours. Surface expression of HLA-ABC or PD-L1 were determined by FACS. mean ± SD, n = 3 biological independent samples, P value by 2-sided t-test. f, A375 shFluc or shLIMIT cells were overexpressed with GBP1 (GBP1OE), and treated with IFNγ for 24 hours. RNA levels of IRF1 were determined by qRT-PCR. mean ± SD, n = 3 biological independent samples, P value by 2-sided t-test. g, Dot plots of intral-tumoral CD8+ T cell infiltration and activation in the YUMM1.7 tumors carrying shFluc, shLimit, shGbp2, or shLimit plus shGbp2. h-i, Correlations between GBP1-5 and LIMIT (h) or MHC-I (i) in human melanoma datasets. P value by 2 sided linear regression. j, Cancer patients having received ICB were divided into low and high GBP groups (bottom 15% vs top 15%). The response rates to ICB were calculated as the percentages of partial response (PR) plus complete response (CR). P value by Chi-square test. Patients were from 4 cohorts. k, Survival plot of patients with melanoma. Based on the expression levels of GBP1-5, patients were divided into high (top 50%) and low (bottom 50%) groups. P value by 2 sided log-rank test. Source data are provided.
